Dysregulation of HSG triggers vascular proliferative disorders
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Vascular proliferative disorders, such as atherosclerosis and restenosis, are the most common causes of severe cardiovascular diseases, but a common molecular mechanism remains elusive. Here, we identify and characterize a novel hyperplasia suppressor gene, named HSG (later re-named rat mitofusin-2). HSG expression was markedly reduced in hyper-proliferative vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rat arteries, balloon-injured Wistar Kyoto rat arteries, or ApoE-knockout mouse atherosclerotic arteries. Overexpression of HSG overtly suppressed serum-evoked VSMC proliferation in culture, and blocked balloon injury induced neointimal VSMC proliferation and restenosis in rat carotid arteries. The HSG anti-proliferative effect was mediated by inhibition of ERK/MAPK signalling and subsequent cell-cycle arrest. Deletion of the p21(ras) signature motif, but not the mitochondrial targeting domain, abolished HSG-induced growth arrest, indicating that rHSG-induced anti-proliferation was independent of mitochondrial fusion. Thus, rHSG functions as a cell proliferation suppressor, whereas dysregulation of rHSG results in proliferative disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Besides its role in mitochondrial fusion, Mfn2 has been described to be involved in the regulation of cell proliferation, oxidative metabolism, autophagy, mitophagy, mitochondrial antiviral signaling, and unfolded protein response (Bach et al, 2003; Chen et al, 2004; Yasukawa et al, 2009; Hailey et al, 2010; Ngoh et al, 2012; Zhao et al, 2012; Chen & Dorn, 2013; Munoz et al, 2013).”
From Mfn2 deficiency links age‐related sarcopenia and impaired autophagy to activation of an adaptive mitophagy pathway (2016) · cites this paper as Chen et al, 2004
In the citing paper
“Recently, it has been reported that Mfn2 binds Ras and its overexpression inhibits extracellular signalrelated kinase/mitogen-activated protein kinase signaling and subsequently arrests cell cycle (30).”
From Expression of Mfn2, the Charcot-Marie-Tooth Neuropathy Type 2A Gene, in Human Skeletal Muscle (2005) · cites this paper as [30]
Citations
Cites
Moses, J. W., Leon, M. B., Popma, J. J., Fitzgerald, P. J., Holmes, D. R., O'Shaughnessy, C., Caputo, R. P., Kereiakes, D. J., Williams, D. O., Teirstein, P. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035071 · Cited by 4,224 · cited 1×
“Recent studies indicate that coated stents with anti-proliferative agents, including rapamyci”
BackgroundMarshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906 · cited 1×
“The Ras proto-oncogene is a central component of mitogenic signalling pathways, and is essential for cells to exit a quiescent state (G0) and to pass through the G1–S transition of the cell cycl”
BackgroundChen, H., Detmer, S. A., Ewald, A. J., Griffin, E. E., Fraser, S. E., & Chan, D. C. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200211046 · Cited by 2,601 · cited 1×
“Several studies have demonstrated that human Mfn-2 and its homologues localize to the mitochondrial outer membrane and have an essential role in mitochondrial fusion, thus regulating mitochondrial morphology and function in mammalian cells, yeast and flie”
BackgroundDevelopment of a Strain of Spontaneously Hypertensive Rats
OKAMOTO, K., & AOKI, K. (1963) · Japanese Circulation Journal · doi:10.1253/jcj.27.282 · Cited by 2,545
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Nakayama, K., Ishida, N., Shirane, M., Inomata, A., Inoue, T., Shishido, N., Horii, I., Loh, D. Y., & Nakayama, K.-I. (1996) · Cell · doi:10.1016/s0092-8674(00)81237-4 · Cited by 1,547
Fero, M. L., Rivkin, M., Tasch, M., Porter, P., Carow, C. E., Firpo, E., Polyak, K., Tsai, L.-H., Broudy, V., Perlmutter, R. M., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81239-8 · Cited by 1,457
Tunstall-Pedoe, H., Kuulasmaa, K., Mähönen, M., Tolonen, H., & Ruokokoski, E. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04021-0 · Cited by 1,444
Clowes, A. W., Reidy, M. A., & Clowes, M. M. (1983) · PubMed · Cited by 1,437
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome
Srivastava, S., Zou, Z., Pirollo, K., Blattner, W., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,211 · cited 1×
“In fact, the anti-proliferative effect of human HSG is more potent than that induced by overexpression of p53, a well established tumour suppresso”
BackgroundControl of mitochondrial morphology by a human mitofusin
Santel, A., & Fuller, M. T. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.5.867 · Cited by 1,012
DeGregori, J., Kowalik, T., & Nevins, J. R. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4215 · Cited by 919 · cited 1×
“When hypo-phosphorylated in the G0/G1 phases of the cell cycle, Rb blocks cell cycle progression by binding to and suppressing the activities of transcription factors such as E2F family member”
BackgroundKarbowski, M., Lee, Y.-J., Gaume, B., Jeong, S.-Y., Frank, S., Nechushtan, A., Santel, A., Fuller, M., Smith, C. L., & Youle, R. J. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200209124 · Cited by 846 · cited 1×
“Several studies have demonstrated that human Mfn-2 and its homologues localize to the mitochondrial outer membrane and have an essential role in mitochondrial fusion, thus regulating mitochondrial morphology and function in mammalian cells, yeast and flie”
BackgroundVascular proliferation and atherosclerosis: New perspectives and therapeutic strategies
Dzau, V. J., Braun-Dullaeus, R. C., & Sedding, D. G. (2002) · Nature Medicine · doi:10.1038/nm1102-1249 · Cited by 831 · cited 1×
“Although vascular smooth muscle cells are normally located primarily in the arterial tunica media and maintained in a non-proliferative state in vivo , injury or mechanical stress of arteries causes migration of VSMCs into the intima layer of the arterial wall, where the VSMCs proliferate and synthesize extracellular…”
BackgroundRequirement of p27 Kip1 for Restriction Point Control of the Fibroblast Cell Cycle
Coats, S., Flanagan, W. M., Nourse, J., & Roberts, J. M. (1996) · Science · doi:10.1126/science.272.5263.877 · Cited by 679
Developmentally Regulated Mitochondrial Fusion Mediated by a Conserved, Novel, Predicted GTPase
Hales, K. G., & Fuller, M. T. (1997) · Cell · doi:10.1016/s0092-8674(00)80319-0 · Cited by 611 · cited 1×
“Several studies have demonstrated that human Mfn-2 and its homologues localize to the mitochondrial outer membrane and have an essential role in mitochondrial fusion, thus regulating mitochondrial morphology and function in mammalian cells, yeast and flie”
BackgroundSignificance of quiescent smooth muscle migration in the injured rat carotid artery.
Clowes, A. W., & Schwartz, S. M. (1985) · Circulation Research · doi:10.1161/01.res.56.1.139 · Cited by 574
Forrester, J. S., Fishbein, M., Helfant, R., & Fagin, J. (1991) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(10)80196-2 · Cited by 557
Rojo, M., Legros, F., Chateau, D., & Lombès, A. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.8.1663 · Cited by 555
Rb function in cell-cycle regulation and apoptosis
Harbour, J. W., & Dean, D. C. (2000) · Nature Cell Biology · doi:10.1038/35008695 · Cited by 509 · cited 1×
“When hypo-phosphorylated in the G0/G1 phases of the cell cycle, Rb blocks cell cycle progression by binding to and suppressing the activities of transcription factors such as E2F family member”
BackgroundBenson, D. A., Boguski, M. S., Lipman, D. J., Ostell, J., Ouellette, B. F. F., Rapp, B. A., & Wheeler, D. L. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.12 · Cited by 494
Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F
Leone, G., DeGregori, J., Sears, R., Jakoi, L., & Nevins, J. R. (1997) · Nature · doi:10.1038/387422a0 · Cited by 468 · cited 1×
“ERK1/2 signalling is also necessary for the degradation or downregulation of CDK inhibitors, such as p21 waf1 (p21) and p27 kip1 (p27), particularly p27, thereby eliminating their growth-suppressive activitie”
BackgroundChang, M. W., Barr, E., Seltzer, J., Jiang, Y.-Q., Nabel, G. J., Nabel, E. G., Parmacek, M. S., & Leiden, J. M. (1995) · Science · doi:10.1126/science.7824950 · Cited by 446
Gene Therapy for Vascular Smooth Muscle Cell Proliferation After Arterial Injury
Ohno, T., Gordon, D., San, H., Pompili, V. J., Imperiale, M. J., Nabel, G. J., & Nabel, E. G. (1994) · Science · doi:10.1126/science.8047883 · Cited by 433
Aktas, H., Cai, H., & Cooper, G. M. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.7.3850 · Cited by 410
Nabel, E. G., Yang, Z.-Y., Plautz, G., Forough, R., Zhan, X., Haudenschild, C. C., Maciag, T., & Nabel, G. J. (1993) · Nature · doi:10.1038/362844a0 · Cited by 367
Vascular biology of atherosclerosis: overview and state of the art
Libby, P. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03143-0 · Cited by 361 · cited 1×
“Numerous growth factors, cytokines and bioactive peptides — for example, platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), endothelin-1 (ET-1) and angiotensin II — have been implicated in VSMC proliferatio”
BackgroundRas signalling linked to the cell-cycle machinery by the retinoblastoma protein
Peeper, D. S., Upton, T. M., Ladha, M. H., Neuman, E., Zalvide, J., Bernards, R., DeCaprio, J. A., & Ewen, M. E. (1997) · Nature · doi:10.1038/386177a0 · Cited by 357
Chang, M. W., Barr, E., Lu, M. M., Barton, K., & Leiden, J. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118281 · Cited by 354
Significance of quiescent smooth muscle migration in the injured rat carotid artery.
WClowes, A., & MSchwartz, S. (1985) · Circulation Research · Cited by 337
Hanke, H., Strohschneider, T., Oberhoff, M., Betz, E., & Karsch, K. R. (1990) · Circulation Research · doi:10.1161/01.res.67.3.651 · Cited by 308
Cell Cycle Progression: New Therapeutic Target for Vascular Proliferative Disease
Braun-Dullaeus, R. C., Mann, M. J., & Dzau, V. J. (1998) · Circulation · doi:10.1161/01.cir.98.1.82 · Cited by 285
Nabel, E. G., Yang, Z., Liptay, S., San, H., Gordon, D., Haudenschild, C. C., & Nabel, G. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116394 · Cited by 237 · cited 1×
“Numerous growth factors, cytokines and bioactive peptides — for example, platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), endothelin-1 (ET-1) and angiotensin II — have been implicated in VSMC proliferatio”
BackgroundBing, O. H. L., Brooks, W. W., Robinson, K. G., Slawsky, M. T., Hayes, J. A., Litwin, S. E., Sens, S., & Conrad, C. H. (1995) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(08)80035-1 · Cited by 214 · cited 1×
“, resulting in spontaneous hypertension at 6–8 weeks of age, and eventually cardiac hypertrophy and heart failure after 18–24 months in half of these rat”
BackgroundFeliciello, I., & Chinali, G. (1993) · Analytical Biochemistry · doi:10.1006/abio.1993.1346 · Cited by 202
Tulis, D. A., Durante, W., Liu, X., Evans, A. J., Peyton, K. J., & Schafer, A. I. (2001) · Circulation · doi:10.1161/hc4701.099585 · Cited by 162
Woods, T. C., & Marks, A. R. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.105243 · Cited by 114
Dobrowolski, S., Harter, M., & Stacey, D. W. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.8.5441 · Cited by 103
Kim, S., Lin, H., Barr, E., Chu, L., Leiden, J. M., & Parmacek, M. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119611 · Cited by 93 · cited 1×
“In addition, recent progress has been made in the development of tissue-specific adenoviral vectors for arterial gene therap”
BackgroundTaylor, D. S., Cheng, X., Pawlowski, J. E., Wallace, A. R., Ferrer, P., & Molloy, C. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1633 · Cited by 86 · cited 1×
“Numerous growth factors, cytokines and bioactive peptides — for example, platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), endothelin-1 (ET-1) and angiotensin II — have been implicated in VSMC proliferatio”
BackgroundOverview of therapies for prevention of restenosis after coronary interventions
Garas, S. M., Huber, P. R., & Scott, N. A. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00168-1 · Cited by 75 · cited 1×
“There is much evidence demonstrating that enhanced VSMC proliferation is essentially involved in the pathogenesis of atherosclerosis and other vascular proliferative disorders, including restenosis after coronary balloon angioplast”
BackgroundDelmas, C., Manenti, S., Boudjelal, A., Peyssonnaux, C., Eychène, A., & Darbon, J.-M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101714200 · Cited by 67 · cited 1×
“ERK1/2 signalling is also necessary for the degradation or downregulation of CDK inhibitors, such as p21 waf1 (p21) and p27 kip1 (p27), particularly p27, thereby eliminating their growth-suppressive activitie”
BackgroundMaillard, L., BELLE, E. V., Tio, F. O., Rivard, A., Kearney, M., Branellec, D., Steg, P. G., Isner, J. M., & Walsh, K. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301255 · Cited by 46
Recent Progress in Gene Therapy for Cardiovascular Disease.
Morishita, R. (2002) · Circulation Journal · doi:10.1253/circj.66.1077 · Cited by 33 · cited 1×
“Recent progress in molecular medicine has led to the development of gene therapy as a new therapeutic option for cardiovascular proliferative disorder”
BackgroundChakir, K., Xiang, Y. K., Yang, D., Zhang, S.-J., Cheng, H., Kobilka, B. K., & Xiao, R.-P. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.5.1048 · Cited by 33
Self-citationJohns, D. G., Webb, R. C., & Charpie, J. R. (2001) · Journal of Hypertension · doi:10.1097/00004872-200101000-00009 · Cited by 33
Devlin, A. M., Gordon, J. F., Davidson, A. O., Clark, J. S., Hamilton, C., Morton, J. J., Campbell, A. M., Reid, J. L., & Dominiczak, A. F. (1995) · Journal of Hypertension · doi:10.1097/00004872-199502000-00008 · Cited by 32
Ferguson, J. E., & Patterson, C. (2003) · Cell Cycle · doi:10.4161/cc.2.3.366 · Cited by 28
Novel methods for adenovirus-mediated gene transfer to blood vessels in vivo
Ooboshi, H., Rios, C., & Heistad, D. D. (1997) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006803202179 · Cited by 21
Cardiovascular disease increasing in developing countries
Novak, K. D. (1998) · Nature Medicine · doi:10.1038/1965 · Cited by 16 · cited 1×
“In particular, vascular proliferative disorders, such as primary atherosclerosis, restenosis after balloon angioplasty, vein-graft disease and coronary arteriosclerosis are the most common causes of severe cardiovascular diseases, the current leading cause of death in the United States and the predicted number one kil…”
Background
Cited by
Mitofusin 2 tethers endoplasmic reticulum to mitochondria
de Brito, O. M., & Scorrano, L. (2008) · Nature · doi:10.1038/nature07534 · Cited by 2,442
Mitochondria: More Than Just a Powerhouse
McBride, H. M., Neuspiel, M., & Wasiak, S. (2006) · Current Biology · doi:10.1016/j.cub.2006.06.054 · Cited by 1,985
Mitochondrial dynamics and apoptosis
Suen, D.-F., Norris, K. L., & Youle, R. J. (2008) · Genes & Development · doi:10.1101/gad.1658508 · Cited by 1,270
Mitochondrial Dynamics — Mitochondrial Fission and Fusion in Human Diseases
Archer, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1215233 · Cited by 1,102
Mitochondrial Dynamics in Mammalian Health and Disease
Liesa, M., Palacín, M., & Zorzano, A. (2009) · Physiological Reviews · doi:10.1152/physrev.00030.2008 · Cited by 953
“Mfn2 (named in the original study as “hyperplasia suppressor gene”, HSG) is repressed in VSMCs under conditions of hyperproliferative states such as atherosclerosis or restenosis (53).”
BackgroundInfluential
Metadata
- Authors
- Chen, K.-H., Guo, X., Ma, D., Guo, Y., Li, Q., Yang, D., Li, P., Qiu, X., Wen, S., Xiao, R.-P., & Tang, J.
- Affiliations
- National Institutes of Health (US)
- Peking University (CN)
- Corresponding author
- Xiao, Rui-Ping
- ORCID
- Venue
- Nature Cell Biology
- Published
- 2004-08-22
- Volume
- 6
- Issue
- 9
- Pages
- 872-883
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- OpenAlex
- W2104828119
- Cited by
- 370
- References
- 50
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 6 · 2023: 12 · 2022: 26 · 2021: 22 · 2020: 18 · 2019: 19 · 2018: 22 · 2017: 18 · 2016: 21 · 2015: 24 · 2014: 20 · 2013: 32 · 2012: 26
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Surgery › Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Keywords
- HSG, mitofusin 2, vascular smooth muscle cell proliferation, restenosis, intimal hyperplasia, atherosclerosis, ERK/MAPK signalling, cell cycle arrest, mitochondrial targeting, mitochondrial fusion, spontaneously hypertensive rats, balloon injury, ApoE-deficient mice
- MeSH terms
- Animals, Arteriosclerosis, Cardiovascular Diseases, Cell Division, Gene Expression Regulation, Humans, Membrane Proteins, Molecular Sequence Data, Muscle, Smooth, Vascular, Oncogene Protein p21(ras), Mice, Knockout, GTP Phosphohydrolases, MAP Kinase Signaling System, Coronary Restenosis, Mitochondrial Proteins, Myocytes, Smooth Muscle, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.